Morphic Holding, Inc. (MORF)
- Previous Close
27.51 - Open
27.27 - Bid 27.99 x 100
- Ask 28.16 x 100
- Day's Range
27.12 - 28.15 - 52 Week Range
19.34 - 63.08 - Volume
302,473 - Avg. Volume
500,819 - Market Cap (intraday)
1.404B - Beta (5Y Monthly) 1.42
- PE Ratio (TTM)
-- - EPS (TTM)
-3.59 - Earnings Date Apr 23, 2024 - Apr 29, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
56.75
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company's products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive. In addition, it has a license agreement with Janssen to discover and develop novel integrin therapeutics; collaboration agreement with Schrödinger for integrin targets; and license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
www.morphictx.comRecent News: MORF
Performance Overview: MORF
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MORF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MORF
Valuation Measures
Market Cap
1.38B
Enterprise Value
674.02M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.24k
Price/Book (mrq)
1.97
Enterprise Value/Revenue
1.29k
Enterprise Value/EBITDA
-3.80
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-20.47%
Return on Equity (ttm)
-29.08%
Revenue (ttm)
521k
Net Income Avi to Common (ttm)
-152.1M
Diluted EPS (ttm)
-3.59
Balance Sheet and Cash Flow
Total Cash (mrq)
704.35M
Total Debt/Equity (mrq)
0.34%
Levered Free Cash Flow (ttm)
-62.01M
Research Analysis: MORF
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell